Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
BURLINGTON, Mass., Feb. 14, 2018 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President, Commercial Operations, will participate in a fireside chat at the RBC Capital Markets 2018 Global Healthcare Conference in New York City on Wednesday, February 21, 2017 at 10:00 am ET. To access the live webcast and subsequent archived recording of the presentation, please visit the Flexion website at http://ir.flexiontherapeutics.com/.
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. Flexion was named one of The Boston Business Journal's 2017 Best Places to Work and one of the Top Places to Work in Massachusetts by The Boston Globe.
Contact:
Scott Young
Vice President, Corporate Communications & Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
[email protected]
